Skip to main content
Clinical Trials/NCT05843552
NCT05843552
Recruiting
Not Applicable

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

University of Minnesota1 site in 1 country30 target enrollmentAugust 14, 2023
ConditionsGaucher Disease
Interventionsno intervention

Overview

Phase
Not Applicable
Intervention
no intervention
Conditions
Gaucher Disease
Sponsor
University of Minnesota
Enrollment
30
Locations
1
Primary Endpoint
EVs quantity
Status
Recruiting
Last Updated
26 days ago

Overview

Brief Summary

This is an observational study intended to generate preliminary data to understand how lysosomal dysfunction can affect the biogenesis of extracellular vesicles, its content and function. The primary objective of the proposed project is to decipher how extracellular vesicle (EV) biogenesis and its role in intercellular communication can be impaired as a consequence of defects in lysosomal function. Collectively these defects in EV biogenesis and function can contribute to the neuroinflammation observed in lysosomal storage diseases. Since EVs can cross the blood-brain barrier, their characterization may be valuable in identifying novel biomarkers. In the presence of a GBA1 mutation, the decrease in GCase activity will lower overall lysosome function and increase the secretion of EVs. Further, there will be differences in EV size, its cargo including lipids, RNA and proteins and their aggregates. In comparison to healthy controls, EVs isolated from patients with Gaucher disease (GD) and GBA1 carriers is hypothesized to show significant differences in terms of its characteristics and content, which can contribute to our understanding of the link between lysosomes and neurological disease.

Registry
clinicaltrials.gov
Start Date
August 14, 2023
End Date
December 31, 2026
Last Updated
26 days ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 18-80yrs
  • Restricted to participants who are untreated, obligate carriers and healthy controls.
  • Participants with GD should have confirmed GD diagnosis, mutation confirmed for carriers and healthy controls confirmed to have no GBA1 mutation by gene sequencing.

Exclusion Criteria

  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.
  • Exclude participants who are currently on therapy for their GD
  • Exclude participants who have any hematological malignancy or other uncontrolled comorbid conditions.

Arms & Interventions

patients with GD

Intervention: no intervention

obligate carriers

Intervention: no intervention

healthy volunteers

Intervention: no intervention

Outcomes

Primary Outcomes

EVs quantity

Time Frame: baseline

Examine EV quantities isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs size

Time Frame: baseline

Examine EV sizes isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs content

Time Frame: baseline

Examine contents in vesicles isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs quantity

Time Frame: 3months

Examine EV quantities isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs size

Time Frame: 3months

Examine EV sizes isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

EVs content

Time Frame: 3months

Examine contents in vesicles isolated from plasma samples collected from patients with GD and carriers and compare to healthy individuals.

Study Sites (1)

Loading locations...

Similar Trials